InnoCare Pharma 诺诚健华(HKEX：09969)

InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline, including one commercial drug BTK inhibitor orelabrutinib, 11 drug candidates on phase I/II/III clinical stage and 5 on IND-enabling stage. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have near 900 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.